Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Thrombosis and bleeding risk and anticoagulant efficacy after hip and knee arthroplasty
ChiCTR2100041689Phase 4Recruiting
- Sponsor
- Second Affiliated Hospital of Kunming Medical University
- Start
- Jan 2021
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Recombinant Proteins and Enzymes, Small Molecules
- Countries
- 1
01
Overview
Phase 4 trial of aspirin, enoxaparin and rivaroxaban in deep vein thrombosis (DVT) and venous thromboembolism (VTE) (3 arms), sponsored by Second Affiliated Hospital of Kunming Medical University. Primary endpoints: Thrombotic event, Bleeding event and 1 more. Started Jan 2021; status: recruiting.
02
Drugs
aspirinenoxaparinrivaroxaban
03
Conditions
deep vein thrombosis (DVT)venous thromboembolism (VTE)
Beyond the preview
Go deeper on ChiCTR2100041689.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2100041689.